Report
EUR 13.44 For Business Accounts Only

SHANDONG WEIGAO GP.MED. sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of SHANDONG WEIGAO GP.MED. (HK), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 25, 2022, the closing price was HKD 10.88 and its potential was estimated at HKD 12.17.
Underlying
Shandong Weigao Group Medical Polymer Co. Ltd. Class H

Shandong Weigao Group Medical Polymer and its subsidiaries are principally engaged in the research and development, production and sale of single-use medical devices and orthopedic products. Co.'s products are categorized into four major categories namely: single use medical consumables and materials; orthopedic materials and instruments; blood purification consumables; and cardiovascular stents. Co. maintains a customer base of approximately 5,400 healthcare organizations and distributors, including more than 2,700 hospitals, over 400 blood stations, over 700 other medical units and over 1,500 trading companies.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch